Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders

Clinical Reviews in Allergy and Immunology

Volumn 50, Issue 3, 2016, Pages 301-311

  Bao, Yan ^a,b   Cao, Xuetao ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Autoimmune disease; B cell; B cell malignancies; Development; Differentiation; Epigenetic regulation

Indexed keywords

AUTOIMMUNITY; B LYMPHOCYTE; BINDING SITE; CELL DIFFERENTIATION; DNA REPAIR; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; AUTOIMMUNE DISEASES; CELL TRANSFORMATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; LEUKEMIA, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOPOIESIS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

TRANSCRIPTION FACTOR;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM DISEASES; LEUKEMIA, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOPOIESIS; TRANSCRIPTION FACTORS;

EID: 84930922258     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-015-8494-7     Document Type: Review

References (118)

1. Clark MR, Mandal M, Ochiai K, Singh H (2014) Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol 14:69–80
2. Bao Y, Cao X (2014) The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review. J Autoimmun 55:10–23
3. Faurschou M, Jayne DR (2014) Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med 65:263–278
4. Yu B, Mao Y, Bai LY, Herman SE et al (2013) Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121:136–147
5. Cooper MD (2015) The early history of B cells. Nat Rev Immunol 15:191–197
6. Reth M, Nielsen P (2014) Signaling circuits in early B-cell development. Adv Immunol 122:129–175
7. De Silva NS, Klein U (2015) Dynamics of B cells in germinal centres. Nat Rev Immunol 15:137–148
8. Li G, Zan H, Xu Z, Casali P (2013) Epigenetics of the antibody response. Trends Immunol 34:460–470
9. Choukrallah MA, Matthias P (2014) The interplay between chromatin and transcription factor networks during B cell development: who pulls the trigger first? Front Immunol 5:156
10. Medvedovic J, Ebert A, Tagoh H, Busslinger M (2011) Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol 111:179–206
11. Mercer EM, Lin YC, Benner C et al (2011) Multilineage priming of enhancer repertoires precedes commitment to the B and myeloid cell lineages in hematopoietic progenitors. Immunity 35:413–425
12. Heinz S, Benner C, Spann N et al (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38:576–589
13. Trowbridge JJ, Snow JW, Kim J, Orkin SH (2009) DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 5:442–449
14. Bröske AM, Vockentanz L, Kharazi S et al (2009) DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 41:1207–1215
15. Challen GA, Sun D, Jeong M et al (2011) Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44:23–31
16. Kong KY, Owens KS, Rogers JH et al (2010) MIR-23A microRNA cluster inhibits B-cell development. Exp Hematol 38:629–640, e1
17. Maier H, Ostraat R, Gao H et al (2004) Early B cell factor cooperates with Runx1 and mediates epigenetic changes associated with mb-1 transcription. Nat Immunol 5:1069–1077
18. Gao H, Lukin K, Ramírez J, Fields S, Lopez D, Hagman J (2009) Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. Proc Natl Acad Sci U S A 106:11258–11263
19. Zouali M (2013) The epigenetic landscape of B lymphocyte tolerance to self. FEBS Lett 587:2067–2073
20. Cho YW, Hong T, Hong S et al (2007) PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J Biol Chem 282:20395–20406
21. McManus S, Ebert A, Salvagiotto G et al (2011) The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells. EMBO J 30:2388–2404
22. Hatta M, Cirillo LA (2007) Chromatin opening and stable perturbation of core histone:DNA contacts by FoxO1. J Biol Chem 282:35583–35593
23. Lin YC, Jhunjhunwala S, Benner C et al (2010) A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat Immunol 11:635–643
24. Kuchen S, Resch W, Yamane A et al (2010) Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 32:828–839
25. O’Carroll D, Mecklenbrauker I, Das PP et al (2007) A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev 21:1999–2004
26. Koralov SB, Muljo SA, Galler GR et al (2008) Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132:860–874
27. Xiao C, Srinivasan L, Calado DP et al (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9:405–414
28. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF (2007) miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 104:7080–7085
29. Xiao C, Calado DP, Galler G et al (2007) MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131:146–159
30. Rao DS, O’Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D (2010) MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 33:48–59
31. Chang TC, Wentzel EA, Kent OA et al (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26:745–752
32. Raver-Shapira N, Marciano E, Meiri E et al (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26:731–743
33. Nakase H, Takahama Y, Akamatsu Y (2003) Effect of CpG methylation on RAG1/RAG2 reactivity: implications of direct and indirect mechanisms for controlling V(D)J cleavage. EMBO Rep 4:774–780
34. Selimyan R, Gerstein RM, Ivanova I et al (2013) Localized DNA demethylation at recombination intermediates during immunoglobulin heavy chain gene assembly. PLoS Biol 11:e1001475
35. Cherry SR, Beard C, Jaenisch R, Baltimore D (2000) V(D)J recombination is not activated by demethylation of the kappa locus. Proc Natl Acad Sci U S A 97:8467–8472
36. Xu CR, Feeney AJ (2009) The epigenetic profile of Ig genes is dynamically regulated during B cell differentiation and is modulated by pre-B cell receptor signaling. J Immunol 182:1362–1369
37. Walter K, Bonifer C, Tagoh H (2008) Stem cell-specific epigenetic priming and B cell-specific transcriptional activation at the mouse Cd19 locus. Blood 112:1673–1682
38. Knoll M, Simmons S, Bouquet C, Grün JR, Melchers F (2013) miR-221 redirects precursor B cells to the BM and regulates their residence. Eur J Immunol 43:2497–2506
39. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K (2004) Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117:787–800
40. Shaffer AL, Lin KI, Kuo TC et al (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17:51–62
41. Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD (2011) The genetic network controlling plasma cell differentiation. Semin Immunol 23:341–349
42. Muto A, Ochiai K, Kimura Y et al (2010) Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J 29:4048–4061
43. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM (1997) Control of inflammation, cytokine expression andgerminal center formation by BCL-6. Science 276:589–592
44. Ye BH, Cattoretti G, Shen Q et al (1997) The BCL-6 proto-oncogene controlsgerminal-centre formation and Th2-type inflammation. Nat Genet 16:161–170
45. Reljic R, Wagner SD, Peakman LJ, Fearon DT (2000) Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med 192:1841–1848
46. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM (2000) BCL-6 represses genes that function in lymphocyte differentiation, inflammation and cell cycle control. Immunity 13:199–212
47. Fujita N, Jaye DL, Geigerman C et al (2004) MTA3 and theMi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119:75–86
48. Fujita N, Jaye DL, Kajita M et al (2003) MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113:207–219
49. Batlle-López A, Cortiguera MG, Rosa-Garrido M et al (2015) Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus. Oncogene 34:246–256
50. Ramachandrareddy H, Bouska A, Shen Y et al (2010) BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells. Proc Natl Acad Sci U S A 107:11930–11935
51. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K (2000) Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol 20:2592–2603
52. Ren B, Chee KJ, Kim TH, Maniatis T (1999) PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes Dev 13:125–137
53. Gyory I, Wu J, Fejér G, Seto E, Wright KL (2004) PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol 5:299–308
54. Ancelin K, Lange UC, Hajkova P et al (2006) Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol 8:623–630
55. Su ST, Ying HY, Chiu YK, Lin FR, Chen MY, Lin KI (2009) Involvement of histone demethylase LSD1 in Blimp-1-mediated gene repression during plasma cell differentiation. Mol Cell Biol 29:1421–1431
56. Ying HY, Su ST, Hsu PH et al (2012) SUMOylation of Blimp-1 is critical for plasma cell differentiation. EMBO Rep 13:631–637
57. Belver L, de Yébenes VG, Ramiro AR (2010) MicroRNAs prevent the generation of autoreactive antibodies. Immunity 33:713–722
58. Thai TH, Calado DP, Casola S et al (2007) Regulation of the germinal center response by microRNA-155. Science 316:604–608
59. Rodriguez A, Vigorito E, Clare S et al (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316:608–611
60. Vigorito E, Perks KL, Abreu-Goodger C et al (2007) microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 27:847–859
61. Dorsett Y, McBride KM, Jankovic M et al (2008) MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 28(5):630–638
62. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28:621–629
63. Shlomchik MJ (2008) Sites and stages of autoreactive B cell activation and regulation. Immunity 28:18–28
64. Vinuesa CG, Sanz I, Cook MC (2009) Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 9:845–857
65. Hertz M, Nemazee D (1997) BCR ligation induces receptor editing in IgM + IgD- bone marrow B cells in vitro. Immunity 6:429–436
66. Melamed D, Nemazee D (1997) Self-antigen does not accelerate immature B cell apoptosis, but stimulates receptor editing as a consequence of developmental arrest. Proc Natl Acad Sci U S A 94:9267–9272
67. Mazari L, Ouarzane M, Zouali M (2007) Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci U S A 104:6317–6322
68. Gupta B, Hawkins RD (2015) Epigenomics of autoimmune diseases. Immunol Cell Biol 93:271–276
69. Garaud S, Le Dantec C, Jousse-Joulin S et al (2009) IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol 182:5623–5632
70. Forster N, Gallinat S, Jablonska J, Weiss S, Elsässer HP, Lutz W (2007) p300 protein acetyltransferase activity suppresses systemic lupus erythematosus-like autoimmune disease in mice. J Immunol 178:6941–6948
71. Thai TH, Patterson HC, Pham DH, Kis-Toth K, Kaminski DA, Tsokos GC (2013) Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse. Proc Natl Acad Sci U S A 110:20194–20199
72. Wang YZ, Tian FF, Yan M et al (2014) Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. Clin Exp Immunol 176:207–221
73. Zhang J, Jia G, Liu Q et al (2015) Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis. Immunology 144:56–67
74. Mok Y, Schwierzeck V, Thomas DC et al (2013) MiR-210 is induced by Oct-2, regulates B cells, and inhibits autoantibody production. J Immunol 191:3037–3048
75. Stagakis E, Bertsias G, Verginis P et al (2011) Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 70:1496–1506
76. Pan W, Zhu S, Yuan M et al (2010) MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 184:6773–6781
77. Garchow BG, Bartulos Encinas O, Leung YT et al (2011) Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med 3:605–615
78. Yuan Y, Kasar S, Underbayev C et al (2012) Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus. Mol Immunol 52:61–70
79. Liu Y, Dong J, Mu R et al (2013) MicroRNA-30a promotes B cell hyperactivity in patients with systemic lupus erythematosus by direct interaction with Lyn. Arthritis Rheum 65:1603–1611
80. Nakasa T, Miyaki S, Okubo A et al (2008) Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 58:1284–1292
81. Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC (2011) Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers 30:171–179
82. Klein U, Dalla-Favera R (2008) Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 8:22–33
83. Chapman MA, Lawrence MS, Keats JJ et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471:467–472
84. Morin RD, Mendez-Lago M, Mungall AJ et al (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298–303
85. Velichutina I, Shaknovich R, Geng H et al (2010) EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116:5247–5255
86. Raaphorst FM, van Kemenade FJ, Fieret E et al (2000) Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 164:1–4
87. van Kemenade FJ, Raaphorst FM, Blokzijl T et al (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97:3896–3901
88. Morin RD, Johnson NA, Severson TM et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181–185
89. Bödör C, O’Riain C, Wrench D et al (2011) EZH2 Y641 mutations in follicular lymphoma. Leukemia 25:726–729
90. Caganova M, Carrisi C, Varano G et al (2013) Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest 123:5009–5022
91. Beguelin W, Popovic R, Teater M et al (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677–692
92. McCabe MT, Ott HM, Ganji G et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–112
93. Knutson SK, Wigle TJ, Warholic NM et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8:890–896
94. Pasqualucci L, Dominguez-Sola D, Chiarenza A et al (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471:189–195
95. Cerchietti LC, Hatzi K, Caldas-Lopes E et al (2010) BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest pii: 42869. doi: 10.1172/JCI42869. [Epub ahead of print]
96. Cerchietti LC, Yang SN, Shaknovich R et al (2009) A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113:3397–3405
97. Giulino-Roth L, Wang K, MacDonald TY et al (2012) Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 120:5181–5184
98. Quesada V, Conde L, Villamor N et al (2011) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44:47–52
99. Zang ZJ, Cutcutache I, Poon SL et al (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44:570–574
100. Guan B, Wang TL, Shih IM (2011) ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71:6718–6127
101. Harada A, Okada S, Konno D et al (2012) Chd2 interacts with H3.3 to determine myogenic cell fate. EMBO J 31:2994–3007
102. Nagarajan P, Onami TM, Rajagopalan S, Kania S, Donnell R, Venkatachalam S (2009) Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 28:1053–1062
103. Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524–15529
104. Döhner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916
105. Rawstron AC, Bennett FL, O’Connor SJ et al (2008) Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359:575–583
106. Avet-Loiseau H, Li JY, Morineau N et al (1999) Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 94:2583–2589
107. Klein U, Lia M, Crespo M et al (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:28–40
108. Cimmino A, Calin GA, Fabbri M et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102:13944–13949
109. He L, Thomson JM, Hemann MT et al (2005) A microRNA polycistron as a potential human oncogene. Nature 435:828–833
110. Costinean S, Zanesi N, Pekarsky Y et al (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 103:7024–7029
111. Basso K, Schneider C, Shen Q et al (2012) BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med 209:2455–2465
112. Kluiver J, Haralambieva E, de Jong D et al (2006) Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosom Cancer 45:147–153
113. Kluiver J, Poppema S, de Jong D et al (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207:243–249
114. Eis PS, Tam W, Sun L et al (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 102:3627–3632
115. Olive V, Bennett MJ, Walker JC et al (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23:2839–2849
116. Mi S, Li Z, Chen P et al (2010) Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A 107:3710–371
117. Mu P, Han YC, Betel D et al (2009) Genetic dissection of the miR-17 ∼ 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23:2806–2811
118. Van Haaften G, Agami R (2010) Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 24:1–4